Janus Henderson Group
KNTE

Janus Henderson Group’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Janus Henderson Group’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-128,182
Closed -$2.27M – 2721
2021
Q4 		$2.27M Buy
128,182
+1,155
+0.9% +$24.4K ﹤0.01% 1234
2021
Q3 		$2.92M Sell
127,027
-475,709
-79% -$10.4M ﹤0.01% 1168
2021
Q2 		$13.5M Sell
602,736
-197,538
-25% -$5.03M 0.01% 872
2021
Q1 		$24.3M Sell
800,274
-5,495
-0.7% -$191K 0.01% 729
2020
Q4 		$30.4M Buy
+805,769
New +$32.3M 0.01% 663

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group's KNTE Position: Q1 2022 in Review

Janus Henderson Group sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q1 2022, closing a stake of 128,182 shares — an estimated $2.27M sold.

Janus Henderson Group first reported a position in KNTE in Q4 2020 and held it in 5 quarters. The position peaked at $30.4M in Q4 2020. 76 funds tracked by Wall St. Rank hold KNTE as of Q1 2022.

  • Janus Henderson Group reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Janus Henderson Group sold 128,182 Kinnate Biopharma Inc. Common Stock shares in Q1 2022, an estimated $2.27M.
  • Janus Henderson Group first reported a position in Kinnate Biopharma Inc. Common Stock in Q4 2020 and held it in 5 quarters.
  • Janus Henderson Group's Kinnate Biopharma Inc. Common Stock position peaked at $30.4M in Q4 2020.
  • 76 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q1 2022.

Based on Janus Henderson Group's 13F filing for Q1 2022, filed 16 May 2022.